AxoGen, Inc.
NASDAQ:AXGNMedical - Devices
+$0.25 today
- Market cap
- $3.40B
- Beta
- 1.12
- P/E (TTM)
- -73.4
- EPS (TTM)
- -$0.61
Volume 2.11M
Average 1.08M
AXGN Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
AxoGen, Inc.NASDAQ: AXGN
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses grows, but more slowly than its trailing trend
Q3 FY2026 operating expenses of $55.78M rose 26.5% year over year, behind the +35.3% change in trailing-twelve-month operating expenses. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.
Context
- Operating expenses amounted to 77.8% of revenue in FY2025, up 0.3 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +26.5% toward the trailing-twelve-month pace of +35.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 175.2M USD
- Year-over-year change
- +20.6%
- 4-year CAGR
- +7.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 175.2M | +20.6% |
| FY2024 | 2024-12-31 | 145.26M | +1.3% |
| FY2023 | 2023-12-31 | 143.33M | +3.5% |
| FY2022 | 2022-12-31 | 138.52M | +6.7% |
| FY2021 | 2021-12-31 | 129.84M | — |
Operating Expenses vs competitors
How AXGN compares with its peers on the latest reported figures
- AXGN's LTM Sep 2026 operating expenses of $211.81M is the 3rd highest of the 7 companies compared; the peer median is $93.5M.
- Its year-over-year change of +35.3% is the highest of 7, against a peer median of -5.9%.
- Operating expenses amounts to 79.4% of revenue for AXGN, versus a peer median of 70.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $350.61M | -4.1% | +4.5% | 68.3% | |
| LTM Mar 2026 | $275.88M | +17.5% | +6.3% | 70.8% | |
| LTM Sep 2026 | $211.81M | +35.3% | +8.1% | 79.4% | |
| LTM Mar 2026 | $98.8M | -9.8% | +5.9% | 4900.7% | |
| LTM Jun 2026 | $88.2M | +0.3% | +10.1% | 110.4% | |
| LTM Mar 2026 | $72.7M | -7.6% | +25.6% | 59.6% | |
| LTM Jun 2026 | -$45.36M | -116.5% | +61.4% | — | |
| Peer median (excluding AXGN) | $93.5M | -5.9% | +8.2% | 70.8% | |
Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 127.36M | 138.58M | 159.01M | 187.34M | 225.21M |
| Cost of Revenue | 22.93M | 29.78M | 37.14M | 45.36M | 57.86M |
| Gross Profit | 104.43M | 108.81M | 121.87M | 141.98M | 167.35M |
| Gross Margin | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% |
| Research & Development | 24.18M | 25.63M | 27.34M | 27.77M | 32.89M |
| Selling, General & Admin | 105.67M | 112.89M | 115.99M | 117.5M | 142.32M |
| Operating Expenses | 129.84M | 138.52M | 143.33M | 145.26M | 175.2M |
| Depreciation & Amortization | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M |
| EBITDA | (20.89M) | (23.47M) | (13.33M) | 6.08M | 192K |
| EBITDA Margin | -16.4% | -16.9% | -8.4% | 3.2% | 0.1% |
| Operating Income | (25.42M) | (29.71M) | (21.46M) | (3.29M) | (7.85M) |
| Operating Margin | -20.0% | -21.4% | -13.5% | -1.8% | -3.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.36M | 624K | 2.84M | 8.21M | 7.7M |
| Other Income / Expenses | (1.57M) | 759K | (254K) | (6.68M) | (7.85M) |
| Income Before Tax | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Pre-Tax Margin | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Net Margin | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| EPS (Basic) | (0.65) | (0.69) | (0.51) | (0.23) | (0.34) |
| EPS (Diluted) | (0.65) | (0.69) | (0.51) | (0.23) | (0.34) |
| Weighted Avg Shares | 41.22M | 42.08M | 42.88M | 44.26M | 46.05M |
| Weighted Avg Shares (Diluted) | 41.22M | 42.08M | 42.88M | 44.26M | 46.05M |
AxoGen, Inc.
NASDAQ:AXGN
Intrinsic Alpha fair value
Locked
Current Price
$56.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.